Simon Read
Director at Dianthus Therapeutics, Inc. /DE/ (DNTH) since May 2025
Simon Read has filed 6 insider reports with the SEC since May 2025, as director at Dianthus Therapeutics, Inc. /DE/ (DNTH). In the last 12 months Simon Read sold $631K of stock on the open market. In the latest filing, on August 19, 2026, Simon Read sold 2,778 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) for $327K at an average of $117.55.
- Filings
- 6
- Companies
- 1
- Bought on market
- None
- Sold on market
- $631K
Companies where Simon Read is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince May 2025 | 0 | $631K | $91.81 | Aug 19, 2026 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Aug 19, 2026-$327KDNTHDirector Read Simon sold $326,554 worth of shares (2,778 units at $117.55) as part of a pre-agreed trading plan and exercised 2,778 shares at a strike of $18.36Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Aug 10, 2026-$304KDNTHDirector Read Simon exercised 2,777 shares at a strike of $18.36 and sold $304,232 worth of shares (2,777 units at $109.55) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Aug 10, 2026~$624KDNTHSimon Read plans to sell 5,550 shares (~$624K)Form 144Planned sale10b5-1 plan
- May 21, 2026DNTHSEC Form 4 filed by Director Read SimonForm 4Grant or award
- May 22, 2025DNTHSEC Form 4 filed by Director Read SimonForm 4Grant or award
- May 22, 2025DNTHSimon Read became an insiderForm 3New insider
Compare Simon Read with
- Simon Read vs Ryan Savitz1 shared
- Simon Read vs Edward Carr1 shared
- Simon Read vs Simrat Randhawa1 shared
- Simon Read vs Adam M Veness1 shared
- Simon Read vs Anne McGeorge1 shared
- Simon Read vs Marino Garcia1 shared
Other insiders at the same companies
- Ryan SavitzDNTH
- Edward CarrDNTH
- Simrat RandhawaDNTH
- Adam M VenessDNTH
- Anne McGeorgeDNTH
- Marino GarciaDNTH
- Alison Frances LawtonDNTH
- Steven J. RomanoDNTH
- Sujay KangoDNTH
- Paula SoteropoulosDNTH
- Jonathan ViolinDNTH
Questions about Simon Read
- What is Simon Read's role at Dianthus Therapeutics, Inc. /DE/?
- Simon Read reports to the SEC as director at Dianthus Therapeutics, Inc. /DE/ (DNTH), according to the latest filing on August 19, 2026.
- Has Simon Read bought or sold stock recently?
- The most recent open-market sale was on August 19, 2026: sold 2,778 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) for $327K at an average of $117.55.
- How do I get alerts when Simon Read files?
- Follow Simon Read on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Simon Read filed 1 time in the last 90 days.
From SEC Forms 3, 4, 5 and 144 filed by Simon Read (SEC CIK 0001688199). Totals count each trade once, skipping amendments whose original is on file, from May 22, 2025 on. View on SEC EDGAR